je.st
news
Tag: parkinsons
Teva and Takeda Agree to Commercialize Rasagiline for Parkinson's Disease Treatment in Japan
2014-04-28 04:37:19| Biotech - Topix.net
Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited have signed an agreement allowing Takeda to commercialize Teva's innovative treatment for Parkinson's disease, rasagiline* in Japan.
Tags: in
japan
agree
treatment
Real-time adaptive brain control: Combining a BCI with DBS to treat Parkinsons
2013-07-17 16:56:52| Extremetech
Perhaps the biggest advance in DBS systems since they were first developed has just been reported by a group of researchers working in the movement disorders group at Oxford University. By recording activity with what is essentially a Brain Computer Interface (BCI), the researchers were able to close the stimulation loop with direct feedback from the subthalamic nucleus. The ability to incorporate meaningful data from the implant user's brain into the moment-to-moment control of the stimulation puts the one-size-fits-all DBS system on the fast track to obsolescence.
Tags: control
treat
brain
combining
Merck Provides Update on Phase III Clinical Program for Preladenant, the Companys Investigational Parkinsons Disease Medicine
2013-05-23 23:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Mercks investigational adenosine A2A receptor antagonist for the treatment of Parkinsons disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo. Language: English Contact HTML: MerckMedia Contacts:Pam Eisele, 908-423-5042orClaire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: program
iii
update
medicine